PDCD1 and melanoma: Comparing the expression profile of low- and high-risk groups with another published dataset containing 47 patients with melanoma that responded to immunotherapy [32], we found that high-risk group tended to respond effectively to immunotherapy such as anti–PD-1 (Bonferroni corrected p = 0.040) and anti-CTLA-4 therapy (p = 0.040) (Figure 6E).